

1 **APPENDIX 17B - GRADE EVIDENCE PROFILES FOR PHARMACOLOGICAL INTERVENTIONS**

2

3 **8.2.3**

4 **Question:** Low dose fluphenazine vs ultra low dose fluphenazine for people who self-harm

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Low dose fluphenazine	Deliberate self harm in self-harming population	Relative (95% CI)	Absolute		
<b>Repetition during 6 months after trial entry</b>												
1	randomised trials	no serious limitations			serious <sup>1</sup>	none	12/27 (44.4%)	9/26 (34.6%)	RR 1.28 (0.65 to 2.52)	97 more per 1000 (from 121 fewer to 526 more)		
								34.6%		97 more per 1000 (from 121 fewer to 526 more)		

5 <sup>1</sup> Total sample size is smaller than 300

6

7 **8.2.2**

8 **Question:** Antidepressants vs Placebo for people who self-harm

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Antidepressants	Placebo	Relative (95% CI)	Absolute		
<b>Per protocol repetition of DSH during first 6 mths</b>												
1	randomised trials	no serious limitations			serious <sup>1,2</sup>	none	16/76 (21.1%)	5/38 (13.2%)	RR 1.6 (0.63 to 4.04)	79 more per 1000 (from 49 fewer to 400 more)		
								13.2%		79 more per 1000 (from 49 fewer to 401 more)		
<b>Per protocol repetition of DSH at last follow up</b>												
1	randomised trials	no serious limitations			serious <sup>1,2</sup>	none	16/76 (21.1%)	5/38 (13.2%)	RR 1.6 (0.63 to 4.04)	79 more per 1000 (from 49 fewer to 400 more)		
								13.2%		79 more per 1000 (from 49 fewer to 400 more)		

Please take note that inconsistency and indirectness were not rated in comparisons that contain only one study

											fewer to 401 more)		
--	--	--	--	--	--	--	--	--	--	--	--------------------	--	--

- 1 <sup>1</sup> Not statistically significant
- 2 <sup>2</sup> Total sample size is smaller than 300
- 3

### 8.2.3

**Question:** Flupenthixol vs Placebo for deliberate self harm in self-harming population

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Flupenthixol	Placebo	Relative (95% CI)	Absolute		
<b>Repetition during 6 months after trial entry</b>												
1	randomised trials	no serious limitations			serious <sup>1</sup>	none	3/14 (21.4%)	12/16 (75%)	RR 0.29 (0.1 to 0.81)	533 fewer per 1000 (from 142 fewer to 675 fewer)		
								75%		533 fewer per 1000 (from 142 fewer to 675 fewer)		
<b>Compliance</b>												
1	randomised trials	no serious limitations				none	14/18 (77.8%)	16/19 (84.2%)	not pooled	not pooled		
								84.2%		not pooled		

- 6 <sup>1</sup> Total sample size is smaller than 300
- 7

### 8.2.4

**Question:** Lithium vs placebo for people who self-harm

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Lithium	Placebo	Relative (95% CI)	Absolute		
<b>Repetition at 12 months from trial entry</b>												
1	randomised trials	no serious limitations			serious <sup>1,2</sup>	none	7/84 (8.3%)	7/83 (8.4%)	RR 0.99 (0.36 to 2.69)	1 fewer per 1000 (from 54 fewer to 143 more)		
								8.4%		1 fewer per 1000 (from 54 fewer to 142 more)		
<b>Depression (HAM-D) - At 3 months (Better indicated by lower values)</b>												
1	randomised	no serious			serious <sup>1,2</sup>	none	59	51	-	SMD 0.05 lower (0.42 lower to		

Please take note that inconsistency and indirectness were not rated in comparisons that contain only one study

CONSULTATION DRAFT

	trials	limitations									0.33 higher)		
<b>Depression (HAM-D) - At 6 months (Better indicated by lower values)</b>													
1	randomised trials	no serious limitations			serious <sup>1,2</sup>	none	47	38	-		SMD 0.07 higher (0.36 lower to 0.5 higher)		
<b>Depression (HAM-D) - At 12 months (Better indicated by lower values)</b>													
1	randomised trials	no serious limitations			serious <sup>1,2</sup>	none	31	33	-		SMD 0.05 lower (0.54 lower to 0.44 higher)		
<b>Hopelessness (BHS) - At 3 months (Better indicated by lower values)</b>													
1	randomised trials	no serious limitations			serious <sup>1,2</sup>	none	45	53	-		SMD 0.1 lower (0.49 lower to 0.3 higher)		
<b>Hopelessness (BHS) - At 6 months (Better indicated by lower values)</b>													
1	randomised trials	no serious limitations			serious <sup>1,2</sup>	none	28	24	-		SMD 0.12 lower (0.67 lower to 0.42 higher)		
<b>Hopelessness (BHS) - At 12 months (Better indicated by lower values)</b>													
1	randomised trials	no serious limitations			serious <sup>1,2</sup>	none	26	25	-		SMD 0.03 lower (0.58 lower to 0.52 higher)		
<b>Depression (HAM-D) - At 3 months (Better indicated by lower values)</b>													
1	randomised trials	no serious limitations			serious <sup>1,2</sup>	none	59	51	-		SMD 0.05 lower (0.42 lower to 0.33 higher)		
<b>Depression (HAM-D) - At 6 months (Better indicated by lower values)</b>													
1	randomised trials	no serious limitations			serious <sup>1,2</sup>	none	47	38	-		SMD 0.07 higher (0.36 lower to 0.5 higher)		
<b>Depression (HAM-D) - At 12 months (Better indicated by lower values)</b>													
1	randomised trials	no serious limitations			serious <sup>1,2</sup>	none	31	33	-		SMD 0.05 lower (0.54 lower to 0.44 higher)		

- 1 <sup>1</sup> Not statistically significant
- 2 <sup>2</sup> Total sample size is smaller than 300
- 3

8.2.4

**Question:** Omega-3 fatty acid supplement vs placebo for people who self-harm

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Omega-3 fatty acid supplement	Control	Relative (95% CI)	Absolute		
Repetition during 12 weeks treatment phase												

Please take note that inconsistency and indirectness were not rated in comparisons that contain only one study

CONSULTATION DRAFT

1	randomised trials	no serious limitations			serious <sup>1,2</sup>	none	7/22 (31.8%)	7/27 (25.9%)	RR 1.23 (0.51 to 2.97)	60 more per 1000 (from 127 fewer to 511 more)		
								25.9%		60 more per 1000 (from 127 fewer to 510 more)		
<b>Depression after 6 mths (Better indicated by lower values)</b>												
1	randomised trials	no serious limitations			serious <sup>1,2</sup>	none	22	27	-	SMD 0.3 lower (0.87 lower to 0.26 higher)		
<b>Adherence</b>												
1	randomised trials	no serious limitations				none	19/22 (86.4%)	20/27 (74.1%)	not pooled	not pooled		
								74.1%		not pooled		
<b>Reported Suicidal ideation at 12 weeks after trial entry</b>												
1	randomised trials	no serious limitations			serious <sup>2</sup>	none	8/27 (29.6%)	14/22 (63.6%)	RR 0.47 (0.24 to 0.9)	337 fewer per 1000 (from 64 fewer to 484 fewer)		
								63.6%		337 fewer per 1000 (from 64 fewer to 483 fewer)		

1 <sup>1</sup> Not statistically significant

2 <sup>2</sup> Total sample size smaller than 300

Please take note that inconsistency and indirectness were not rated in comparisons that contain only one study